Abstract: Being widely used for the treatment of many types of cancers, immune checkpoint inhibitors have received extensive attention as a landmark in the development of anti-cancer therapy. With their more extensive clinical application, organ specific adverse reactions have become increasingly prominent, especially myocarditis. As one of the cardiovascular adverse effects, myocarditis has a high fatality rate and should be brought to the forefront. Glucocorticoid and immunosuppressants are the mainstays of current treatment. Routine monitoring of cardiovascular adverse effects is essential for patients receiving treatment with immune checkpoint inhibitors.